![](/fileadmin/_processed_/csm_NCI-radiopharma_21ffe1bccf.png)
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek....
![](/fileadmin/_processed_/csm_tubulis_linker_ADC_web_bccd46dac0.jpg)
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis, based in Martinsried near Munich, announced today that the first patient has been treated in its first Phase 1/2a...
![](/fileadmin/_processed_/csm_DKFZ_abcda82777.jpg)
Protein flags Car-T cells for digestion by NK cells
The protein B7H6, which is highly expressed on activated human T cells, can flag the cells for clearance by natural killer (NK) cells, weakening the...
![](/fileadmin/_processed_/csm_Roche3_cd0afd0272.png)
Obesity: Roche with first clinical data after US$2.7bn deal
Following the acquisition of Carmot Therapeutics in December 2023 for US$2.7bn biobucks (US$400m upfront), Roche has now announced the results of...
![](/fileadmin/_processed_/csm_Labmate-currency-2317703_1280_be218675b3.jpg)
LabGenius raises £35m to expand its antibody discovery platform
The investment brings LabGenius’ total funding to £58m. The new round was led by new investor M Ventures (Merck’s venture capital). New investors...
![](/fileadmin/_processed_/csm_anacura_griet_ohmxbio_104d007f0f.jpg)
Anacura aquires Ohmx.bio
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a also...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...